20-F: Bon Natural Life Limited Reports Fiscal Year 2024 Results: Revenue Declines Amid Strategic Shift

Bon Natural Life Limited's fiscal year 2024 saw a revenue decrease due to changing market dynamics and a strategic focus on bioactive food ingredients.

Summary

• Bon Natural Life Limited reported a decrease in revenue for fiscal year 2024, totaling $23.8 million compared to $29.5 million in fiscal year 2023.
• The decline is attributed to reduced sales volumes in fragrance compounds and health supplements, offset by growth in bioactive food ingredients.
• The company experienced a net income of $345,248, significantly lower than the $4.5 million reported in the previous fiscal year.
• Gross profit decreased to $7.1 million from $8.8 million year-over-year, with a slight decrease in gross margin from 29.9% to 29.8%.
• Operating expenses increased to $5.2 million, driven by higher general and administrative, and research and development costs.
• The company is addressing material weaknesses in internal control over financial reporting by hiring qualified personnel and implementing training programs.
• Bon Natural Life is navigating complex and rapidly evolving laws and regulations in China, which could impact its operations and the value of its ordinary shares.
• The company is focusing on expanding its presence in the bioactive food ingredients market while managing challenges in the fragrance and health supplement sectors.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positives like the focus on bioactive food ingredients and efforts to improve internal controls, the significant decline in revenue and net income, along with identified material weaknesses, weighs heavily on the overall sentiment.

Positives

• Sales volumes of bioactive food ingredients increased by 8.0% for the year ended September 30, 2024.
• The company is taking steps to remediate material weaknesses in internal control over financial reporting.
• The company is focusing on expanding its presence in the bioactive food ingredients market.

Negatives

• Revenue decreased by 19.2% to $23.8 million.
• Net income significantly declined to $345,248 from $4.5 million.
• Sales volumes of fragrance compounds and health supplements decreased.
• Operating expenses increased by 80.3% to $5.2 million.
• Material weaknesses exist in internal control over financial reporting.

Risks

• Complex and rapidly evolving laws and regulations in China could impact the company's operations and the value of its ordinary shares.
• The company faces increased competition from new and existing firms with greater capital resources.
• The company's products have not been clinically proven to be safe or effective.
• The company may incur material product liability claims.
• The company may not be able to protect its intellectual property rights.
• The company may rely on dividends and other distributions on equity paid by its PRC subsidiary to fund any cash and financing requirements it may have, and any limitation on the ability of its PRC subsidiary to make payments to it could have a material and adverse effect on its ability to conduct its business.

Future Outlook

The company plans to expand its plants, increase productivity, improve technology and equipment, optimize its supply chain, and broaden its sales channels to ensure steady and sustainable growth. Management is committed to achieving a compound annual growth rate in this business line of no less than 30%.

Industry Context

The company operates in the competitive natural products and ingredients industry, facing challenges from larger, more established companies. The company is focusing on the human micro-biome health market, which is a relatively new and fast-growing product focus.

Comparison to Industry Standards

• The company faces competition from Chenguang Biotech, a leading natural colors supplier in China, and Layn, a natural sweeteners supplier.
• European counterparts like Koninklijke DSM N.V., Symrise AG, and Givaudan SA also pose competitive challenges.
• The company's ambroxide products are produced with 99.5% purity and above, while the industry average is approximately 99.0%.
• The yield of the company's ambroxide production is approximately 63%, while the industry average yield is approximately 40% to 43%.

Related Party Transactions

• As of September 30, 2024 and 2023, the balance of due to related parties was comprised of the Company's borrowings from related parties and was used for working capital during the Company's normal course of business.
• As of September 30, 2024 and 2023, the balance of due from related parties was mainly comprised of advance to the employees for business purposes.
• In connection with the Company's short-term and long-term loans borrowed from PRC banks and other financial institutions, the Company's controlling shareholder, Mr. Yongwei Hu pledged his personal bank savings as collateral to safeguard the Company's borrowings from the banks and financial institutions.
• Mr. Yongwei Hu and his wife Ms. Jing Liu also jointly pledged their personal residence property to guarantee the Company's certain loans.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and net income.
• Employees may be affected by the company's efforts to improve internal controls.
• Customers may be impacted by the company's strategic shift towards bioactive food ingredients.

Next Steps

• The company intends to expand its plants, increase productivity, improve technology and equipment, optimize its supply chain, and broaden its sales channels to ensure steady and sustainable growth.
• The company will continue to implement remedial measures to address material weaknesses in internal control over financial reporting.

Key Dates

Keywords

revenue, financial results, bioactive food ingredients, fragrance compounds, health supplements, internal control, China, financial reporting, operating expenses, net income